- Key business and commercial milestones and goals met
- Global presence further strengthened with subsidiaries in the U.S., UK, France and the Netherlands
Curetis N.V. (the “Company” and, together with Curetis GmbH, “Curetis“), a developer of next-level molecular diagnostic solutions, today reported its financial results for the first six months ended June 30, 2016, and provided an update on its financial and business guidance for the second half 2016 and beyond.
Operational and Business Highlights 2016 to Date » Read more...
Agena Bioscience today announced accreditation of its Assays by Agena facility in Brisbane, Australia, under ISO/IEC 17025 in the field of biological testing for determinations of SNP Genotyping, somatic mutation detection, and quantitative methylation analysis using its MassARRAY® System.
The accreditation comes from the National Association of Testing Authorities, or NATA, and ensures that member facilities comply with standards and provide accurate data generation, controlled test methods and procedures, and properly trained personnel.
Agena Bioscience CEO Peter Dansky commented, “Accreditation of our facility in Brisbane demonstrates the company’s commitment to advance the MassARRAY System into the clinical market, and ensure consistent, valid, and robust results under documented quality management systems.” » Read more...